Literature DB >> 7621871

A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells.

I Mendel1, N Kerlero de Rosbo, A Ben-Nun.   

Abstract

A predominant response to myelin oligodendrocyte glycoprotein (MOG) was recently observed in patients with multiple sclerosis (MS). To study the possible pathogenic role of T cell response to MOG in MS, we have investigated the encephalitogenic potential of MOG. Synthetic MOG peptides, pMOG 1-21, 35-55, 67-87, 104-117 and 202-218, representing predicted T cell epitopes, were injected into C57BL/6J and C3H.SW (H-2b) mice. The mice developed significant specific T cell responses to pMOG 1-21, pMOG 35-55 and pMOG 104-117. However, pMOG 35-55 was the only MOG peptide which could induce neurological impairment. The highly reproducible disease was chronic, with ascending paralysis and neuropathology comparable with those observed in experimental autoimmune encephalomyelitis (EAE) induced by myelin basic protein or proteolipid protein, except that in H-2b mice the disease was consistently non-remitting. These features differ markedly from those which we recently observed in PL (H-2u) mice with pMOG 35-55-induced disease. In PL mice, pMOG 35-55-induces atypical chronic relapsing EAE, the expression and progression of which are unpredictable. Hence, in different mouse strains, the same MOG peptide can induce typical EAE characterized by ascending paralysis, or atypical EAE with unpredictable clinical signs. pMOG 35-55-specific T cells from H-2b mice recognized an epitope within amino acids 40-55 of the MOG molecule, and pMOG 40-55-reactive T cell lines were encephalitogenic upon transfer into syngeneic recipients. The encephalitogenic pMOG 35-55-reactive C57BL/6J T cell lines expressed V beta 1, V beta 6, V beta 8, V beta 14 and V beta 15 gene segments, and the pMOG 35-55-reactive C3H.SW T cell lines expressed V beta 1, V beta 2, V beta 6, V beta 8, V beta 10, V beta 14, and V beta 15 gene segments. However, in both mouse strains, the utilization of the V beta 8 gene product was predominant (40-43%). The highly reproducible encephalitogenic activity of pMOG 35-55 strongly suggests a pathogenic role for T cell reactivity to MOG in MS and supports the possibility that MOG may also be a primary target antigen in the disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7621871     DOI: 10.1002/eji.1830250723

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  178 in total

1.  Reversal of the CD4(+)/CD8(+) T-cell ratio in lymph node cells upon in vitro mitogenic stimulation by highly purified, water-soluble S3-S4 dimer of pertussis toxin.

Authors:  R Latif; N Kerlero de Rosbo; T Amarant; R Rappuoli; G Sappler; A Ben-Nun
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Impairment of TNF-receptor-1 signaling but not fas signaling diminishes T-cell apoptosis in myelin oligodendrocyte glycoprotein peptide-induced chronic demyelinating autoimmune encephalomyelitis in mice.

Authors:  R Bachmann; H P Eugster; K Frei; A Fontana; H Lassmann
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

3.  Gene-expression profiling of experimental autoimmune encephalomyelitis.

Authors:  Eilhard Mix; Jens Pahnke; Saleh M Ibrahim
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

Review 4.  Defining the parameters necessary for T-cell recognition of ligands that vary in potency.

Authors:  Neely E Kilgore; Mandy L Ford; Carrie D Margot; Daniel S Jones; Peter Reichardt; Brian D Evavold
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

5.  Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response.

Authors:  Birgit Liliensiek; Markus A Weigand; Angelika Bierhaus; Werner Nicklas; Michael Kasper; Stefan Hofer; Jens Plachky; Herman-Josef Gröne; Florian C Kurschus; Ann Marie Schmidt; Shi Du Yan; Eike Martin; Erwin Schleicher; David M Stern; G ünterJ Hämmerling G; Peter P Nawroth; Bernd Arnold
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

Review 6.  Immune checkpoints in central nervous system autoimmunity.

Authors:  Nicole Joller; Anneli Peters; Ana C Anderson; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

7.  B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity.

Authors:  Martin S Weber; Thomas Prod'homme; Juan C Patarroyo; Nicolas Molnarfi; Tara Karnezis; Klaus Lehmann-Horn; Dimitry M Danilenko; Jeffrey Eastham-Anderson; Anthony J Slavin; Christopher Linington; Claude C A Bernard; Flavius Martin; Scott S Zamvil
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

8.  Role of pathogenic T cells and autoantibodies in relapse and progression of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in LEW.1AV1 rats.

Authors:  Yoh Matsumoto; Il-Kwon Park; Keiko Hiraki; Shin Ohtani; Kuniko Kohyama
Journal:  Immunology       Date:  2008-10-29       Impact factor: 7.397

9.  Differential upregulation of heme oxygenase-1 (HSP32) in glial cells after oxidative stress and in demyelinating disorders.

Authors:  Thomas Stahnke; Christine Stadelmann; Anne Netzler; Wolfgang Brück; Christiane Richter-Landsberg
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

10.  T cell receptor CDR3 sequence but not recognition characteristics distinguish autoreactive effector and Foxp3(+) regulatory T cells.

Authors:  Xin Liu; Phuong Nguyen; Wei Liu; Cheng Cheng; Meredith Steeves; John C Obenauer; Jing Ma; Terrence L Geiger
Journal:  Immunity       Date:  2009-12-10       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.